NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- oncolytic type 2 herpes simplex virus expressing granulocyte macrophage colony-stimulating factor OH2
A genetically engineered, ICP34.5- and ICP47-deleted oncolytic human herpes simplex type-2 virus (HSV-2), derived from the HG52 strain, encoding the immunostimulating factor cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon administration, the oncolytic HSV-2 expressing GM-CSF OH2 selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T-cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells. Mutation of the ICP6 gene, which encodes the large subunit of the viral ribonucleotide reductase, in the viral vector also enhances selective replication in tumor cells.
Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: HG52/ICP34.5-/ICP47- HSV-2-expressing GM-CSF OH2
oHSV-2-expressing GM-CSF OH2
oncolytic HSV-2-expressing GM-CSF OH2
Abbreviation: OH2 Code name: OH 2